Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.

Manno, Daniela; Bangura, Agnes; Baiden, Frank; Kamara, Abu Bakarr; Ayieko, Philip; Kallon, Joseph; Foster, Julie; Conteh, Musa; Connor, Nicholas Edward; Koroma, Bockarie; +20 more... Njie, Yusupha; Borboh, Paul; Keshinro, Babajide; Lawal, Bolarinde Joseph; Kroma, Mattu Tehtor; Otieno, Godfrey Tuda; Deen, Abdul Tejan; Choi, Edward Man-Lik; Balami, Ahmed Dahiru; Gaddah, Auguste; McLean, Chelsea; Luhn, Kerstin; Adetola, Hammed Hassan; Deen, Gibrilla Fadlu; Samai, Mohamed; Lowe, Brett; Robinson, Cynthia; Leigh, Bailah; Greenwood, Brian; Watson-Jones, Deborah; (2022) Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial. The Lancet. Infectious diseases, 23 (3). pp. 352-360. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(22)00594-1

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(22)00594-1

Abstract

Share

Download

Filename: Manno-etal-2022-Safety-and-immunogenicity-of-an-Ad26.ZEBOV-booster-dose.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar